Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
ESMO 2022: Highlights, commentary and analysis
Dr Bishal Gyawali - Queen's University, Kingston, Canada
ESMO 2022: Highlights, commentary and analysis ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )
12 Sep 2022
Sotorasib shows superior PFS and ORR compared to docetaxel for NSCLC
Dr Silvia Novello - University of Turin, Turin, Italy
Sotorasib shows superior PFS and ORR compared to docetaxel for NSCLC ( Dr Silvia Novello - University of Turin, Turin, Italy )
12 Sep 2022
ESMO 2022: Renal roundup
Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA
ESMO 2022: Renal roundup ( Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA )
12 Sep 2022
ESMO 2022: Breast cancer highlights
Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy
ESMO 2022: Breast cancer highlights ( Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy )
12 Sep 2022
Cabozantinib in combination w/ nivolumab and ipilimumab of IMDC intermediate or ...
Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA
Cabozantinib in combination w/ nivolumab and ipilimumab of IMDC intermediate or poor risk significantly improved PFS vs PBO ( Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA )
12 Sep 2022
Lenvatinib plus pembro for aRCC - update on the CLEAR study
Dr Bradley McGregor - Dana-Farber Cancer Institute, Boston, USA
Lenvatinib plus pembro for aRCC - update on the CLEAR study ( Dr Bradley McGregor - Dana-Farber Cancer Institute, Boston, USA )
12 Sep 2022
Abemaciclib plus NSAI for HR+, HER2- advanced breast cancer - MONARCH 3 interim ...
Prof Matthew P Goetz - Mayo Clinic, Rochester, USA
Abemaciclib plus NSAI for HR+, HER2- advanced breast cancer - MONARCH 3 interim data ( Prof Matthew P Goetz - Mayo Clinic, Rochester, USA )
12 Sep 2022
Optimum treatment strategy algorithm for mCRC
Prof Heinz-Josef Lenz - USC Norris Comprehensive Cancer Center, Los Angeles, USA
Optimum treatment strategy algorithm for mCRC ( Prof Heinz-Josef Lenz - USC Norris Comprehensive Cancer Center, Los Angeles, USA )
15 Aug 2022
Prostate roundup what have we learned from EAU and ASCO 2022?
Prof Eleni Efstathiou and Prof Nicolas Mottet
Prostate roundup what have we learned from EAU and ASCO 2022? ( Prof Eleni Efstathiou and Prof Nicolas Mottet )
11 Jul 2022
Lung cancer immunotherapy adjuvant and neoadjuvant indications
Dr. Luis Raez - Memorial Healthcare System, Florida, USA
Lung cancer immunotherapy adjuvant and neoadjuvant indications ( Dr. Luis Raez - Memorial Healthcare System, Florida, USA )
8 Jul 2022
Treatment with high-dose multi-agent chemotherapy for high-risk lymphoma is effe...
Dr Martine Chamuleau - Amsterdam UMC, Amsterdam, Netherlands
Treatment with high-dose multi-agent chemotherapy for high-risk lymphoma is effective but with significant toxicity ( Dr Martine Chamuleau - Amsterdam UMC, Amsterdam, Netherlands )
14 Jun 2022
Comment: Addition of ixazomib to pomalidomide and dexamethasone improves surviva...
Dr Paul Richardson - Dana Farber Cancer Institute, Boston, USA
Comment: Addition of ixazomib to pomalidomide and dexamethasone improves survival for multiple myeloma patients ( Dr Paul Richardson - Dana Farber Cancer Institute, Boston, USA )
14 Jun 2022